Earlier this year, researchers identified a new intradermal melanoma model for melanoma immunotherapy combination studies, the Cloudman S91. The article, “Cloudman S91 – a responsive syngeneic melanoma model” by Sumithra Urs, PhD, Senior Scientist, Scientific Development, Labcorp, described how SARRP was used to evaluate the tumor model’s sensitivity to radiation. The study found dose-dependent tumor regression from single radiation treatments.
Learn more below and view the original article here.
